Table 2. Bivariate analysis: Baseline characteristics and their correlation with risk of BPH progression.
Variable | Estimate | SE | p-value | HR |
---|---|---|---|---|
Age, year | 0.0373 | 0.0072 | <.0001 | 1.038 |
AUA Symptom Score | −0.0240 | 0.0093 | 0.0098 | 0.976 |
Prostate volume, ml | 0.0096 | 0.0021 | <.0001 | 1.010 |
Maximal urinary flow rate, ml/sec | −0.0587 | 0.0204 | 0.004 | 0.943 |
Post-voiding residual volume, ml | 0.0018 | 0.0005 | 0.001 | 1.002 |
Serum PSA, ng/ml | 0.1096 | 0.0223 | <.0001 | 1.116 |
BPH Impact Index | 0.0452 | 0.0192 | 0.0184 | 1.046 |
Serum glucose, ng/dl | −0.0005 | 0.0013 | 0.7126 | 1.000 |
BMI, kg/m2 | −0.0018 | 0.0130 | 0.8930 | 0.998 |
Primary school education only, yes vs. no | 0.3511 | 0.2420 | 0.1469 | 1.421 |
Family history of prostate cancer | ||||
Yes | −0.0757 | 0.1597 | 0.6357 | 0.927 |
No | 1.00 (reference) | |||
Unknown | 0.2040 | 0.1480 | 0.1682 | 1.226 |
Impotence, n (%) | ||||
Yes | 0.2117 | 0.1194 | 0.0762 | 1.236 |
No | 1.00 (reference) | |||
Intermittent | 0.0072 | 0.1374 | 0.9583 | 1.007 |
History of diabetes, yes vs. no | 0.0826 | 0.1854 | 0.6561 | 1.086 |
History of hypertension, yes vs. no | 0.0173 | 0.1186 | 0.8843 | 1.017 |
SE = standard error; HR = hazard ratio; CL = confidence limit; PSA = prostate-specific antigen; AUA = American Urological Association